IPHA Stock Analysis: Buy, Sell, or Hold?
IPHA - Innate Pharma S.A. ADS
$1.80
-0.01 (-0.55%)
▼
5d:
+0.56%
30d:
-1.1%
90d:
+33.33%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Sep 17, 2026
Get Alerted When IPHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IPHA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IPHA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IPHA is currently trading at $1.80, which is considered fair relative to its 30-day fair value range of $1.74 to $1.83.
Technical Outlook: Technically, IPHA is showing sideways momentum. Immediate support is located at $1.71, while resistance sits at $1.92.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+233.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IPHA is showing sideways momentum. Immediate support is located at $1.71, while resistance sits at $1.92.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+233.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.74 -
$1.83
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 233.3% below Wall St target ($6.00)
Trading Range Analysis
30-Day Trading Range
$1.74 -
$1.83
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.71
Resistance Level
$1.92
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.84
Wall Street Target
$6.00
(+233.3%)
Revenue Growth (YoY)
-46.7%
Earnings Growth (YoY)
-74.7%
Share & Embed Analysis
Last updated: July 04, 2026 9:03 AM ET
Data refreshes hourly during market hours. Next update: 10:03 AM
Data refreshes hourly during market hours. Next update: 10:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IPHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 67 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
